By David Bautz, PhD
NASDAQ:FBLG
READ THE FULL FBLG RESEARCH REPORT
On September 10, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced significant progress has been made in the advancement of the company’s Bone Marrow Organoid platform, which may lead to new treatment options for blood cancers and age-related immune decline.
The company announced that pre-IND animal studies using a xenograft melanoma mouse model showed that following Bone Marrow Organoid transplantation, there was a significant reduction in tumor size. In addition, the Bone Marrow Organoid platform is amenable to ex vivo gene editing, which means that alterations to the cell’s genomes can be performed prior to transplantation. This method of genetic modification is safer than in vivo gene editing, which occurs inside the body, as it allows the modifications to be produced in the laboratory and monitored for any potential unexpected or undesired effects prior to introducing them into the patient. Lastly, the Bone Marrow Organoids are amenable to cryopreservation, which we believe could make them a scalable treatment option for bone marrow transplantation.
The company has multiple “organoid” programs in development, including the Artificial Thymus Organoid, the Bone Marrow Organoid, and the Artificial Pancreatic Organoid. Each of these programs seeks to replicate at least part of the function of an organ or tissue. For example, FibroBiologics previously announced that its Artificial Thymus Organoid gives rise to functional αβ T cells, δγ T cells, NKT cells, and T regulatory cells, thus potentially being useful for correcting age-related thymic decline (Gebremeskel et al., 2025). While the organoid programs are still in the pre-clinical stage of development, they represent potential upside for the company as it focuses on fibroblast therapies for chronic diseases.
Conclusion
The use of a fibroblast-based organoid to replicate the actions of a diseased organ or tissue represents a compelling opportunity for the company and we look forward to additional updates regarding each of these programs as they advance in pre-clinical testing. As a reminder, we continue to expect the initiation of a Phase 1/2 trial of CYWC628 in patients suffering from diabetic foot ulcers to initiate in the first quarter of 2026, with topline results likely in the second half of 2026. With no changes to our model our valuation remains at $11 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.